Casdin Capital 13F holdings, Q4 2020
Holdings as of December 31, 2020 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 50 US equity positions worth $3.4bn in its Q4 2020 13F filing. The largest position was INVITAE CORP at 15.3% of the reported book, followed by BLFS and FATE. Against the Q3 2020 filing, it opened 11 new positions, added to 11 and reduced 2 among the top 50 holdings.
What did Casdin Capital own in Q4 2020? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2020 |
|---|---|---|---|---|---|---|---|
| 1 | INVITAE CORP | 15.3% | $514.2m | 12,298,038 | 36% | added | |
| 2 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 8.8% | $296.8m | 7,440,107 | 27% | added |
| 3 | FATE FATE THERAPEUTICS INC | Healthcare | 8.3% | $277.3m | 3,050,000 | 0% | held |
| 4 | EXK EXACT SCIENCES CORP | Basic Materials | 5.9% | $196.8m | 1,485,149 | – | new |
| 5 | 2655787D BLUEPRINT MEDICINES CORP | 5.2% | $173.8m | 1,550,000 | 0% | held | |
| 6 | RLAY RELAY THERAPEUTICS INC | Healthcare | 4.7% | $158.3m | 3,808,894 | 0% | held |
| 7 | TWST TWIST BIOSCIENCE CORP | Healthcare | 4.2% | $141.3m | 1,000,000 | 0% | held |
| 8 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 3.9% | $129.7m | 5,000,000 | 11% | added |
| 9 | DNLI DENALI THERAPEUTICS INC | Healthcare | 3.3% | $109.7m | 1,310,000 | 0% | held |
| 10 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 3.1% | $102.9m | 2,375,000 | 36% | added |
| 11 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.0% | $101.4m | 780,000 | 26% | added |
| 12 | CDXS CODEXIS INC | Healthcare | 2.8% | $94.5m | 4,330,000 | 9% | added |
| 13 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 2.7% | $90.4m | 530,000 | 0% | held |
| 14 | CDNA CAREDX INC | Healthcare | 2.6% | $86.5m | 1,193,335 | 0% | held |
| 15 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.9% | $64.7m | 1,634,535 | 0% | held |
| 16 | CNST CONSTELLATION PHARMCETICLS I | 1.5% | $51.4m | 1,785,000 | 82% | added | |
| 17 | GENERATION BIO CO | 1.4% | $45.7m | 1,611,214 | 0% | held | |
| 18 | DERMTECH INC | 1.3% | $44.4m | 1,370,000 | -4% | reduced | |
| 19 | BNR BURNING ROCK BIOTECH LTD | 1.3% | $44.4m | 1,922,150 | 0% | held | |
| 20 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 1.3% | $42.2m | 713,125 | 0% | held |
| 21 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.2% | $40.8m | 266,430 | 0% | held |
| 22 | BLUEBIRD BIO INC | 1.2% | $39.6m | 915,000 | 0% | held | |
| 23 | ADVERUM BIOTECHNOLOGIES INC | 1.2% | $39.6m | 3,650,000 | 33% | added | |
| 24 | ONC BEIGENE LTD | Healthcare | 1.2% | $38.8m | 150,000 | 0% | held |
| 25 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.1% | $37.6m | 460,000 | – | new |
| 26 | GLOBAL BLOOD THERAPEUTICS IN | 1.0% | $35.1m | 810,000 | 105% | added | |
| 27 | 4D MOLECULAR THERAPEUTICS IN | 1.0% | $32.4m | 780,555 | – | new | |
| 28 | MAGENTA THERAPEUTICS INC | 0.8% | $26.2m | 3,346,034 | 0% | held | |
| 29 | ZLAB ZAI LAB LTD | Healthcare | 0.8% | $25.7m | 190,000 | 0% | held |
| 30 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.8% | $25.5m | 550,000 | 90% | added |
| 31 | ALEC ALECTOR INC | Healthcare | 0.7% | $25.0m | 1,650,000 | 0% | held |
| 32 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 0.7% | $23.9m | 945,000 | 0% | held |
| 33 | MASS 908 DEVICES INC | 0.7% | $23.1m | 406,502 | – | new | |
| 34 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.6% | $21.8m | 820,440 | 0% | held |
| 35 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.6% | $20.4m | 601,515 | 139% | added |
| 36 | BERKELEY LTS INC | 0.5% | $17.9m | 200,000 | 0% | held | |
| 37 | KRONOS BIO INC | 0.5% | $17.4m | 583,436 | – | new | |
| 38 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 0.5% | $16.9m | 1,080,000 | 0% | held |
| 39 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.4% | $14.5m | 1,241,176 | -14% | reduced |
| 40 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.3% | $10.0m | 450,000 | – | new |
| 41 | BLACK DIAMOND THERAPEUTICS I | 0.3% | $9.3m | 289,395 | 0% | held | |
| 42 | TURNING POINT THERAPEUTICS I | 0.3% | $9.1m | 75,000 | 0% | held | |
| 43 | SEER SEER INC | 0.3% | $8.4m | 150,000 | – | new | |
| 44 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 0.2% | $8.0m | 200,000 | – | new |
| 45 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.2% | $7.8m | 370,000 | 0% | held |
| 46 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.2% | $7.4m | 120,000 | 0% | held |
| 47 | FHTX FOGHORN THERAPEUTICS INC | Healthcare | 0.1% | $4.4m | 216,216 | – | new |
| 48 | BRISTOL-MYERS SQUIBB CO | 0.1% | $4.3m | 6,250,000 | 0% | held | |
| 49 | CODIAK BIOSCIENCES INC | 0.1% | $2.5m | 76,688 | – | new | |
| 50 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.0% | $1.3m | 40,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.